Abundant evidence connects depression symptomology with immune system activation, stress and subsequently elevated levels of kynurenine. Anti-depressants, such as the tricyclic norepinephrine/serotonin reuptake inhibitor desipramine (Desip), were developed under the premise that increasing extracellular neurotransmitter level was the sole mechanism by which they alleviate depressive symptomologies. However, evidence suggests that anti-depressants have additional actions that contribute to their therapeutic potential. The Kynurenine Pathway produces tryptophan metabolites that modulate neurotransmitter activity. This recognition identified another putative pathway for anti-depressant targeting. Considering a recognized role of the Kynurenine Pathway in depression, we investigated the potential for Desip to alter expression of rate-limiting enzymes of this pathway: indoleamine-2,3-dioxygenases (Ido1 and Ido2). Mice were administered lipopolysaccharide (LPS) or synthetic glucocorticoid dexamethasone (Dex) with Desip to determine if Desip alters indoleamine-dioxygenase (DO) expression in vivo following a modeled immune and stress response. This work was followed by treating murine and human peripheral blood mononuclear cells (PBMCs) with interferon-gamma (IFNc) and Desip. In vivo: Desip blocked LPS-induced Ido1 expression in hippocampi, astrocytes, microglia and PBMCs and Ido2 expression by PBMCs. Ex vivo: Desip decreased IFNc-induced Ido1 and Ido2 expression in murine PBMCs. This effect was directly translatable to the human system as Desip decreased IDO1 and IDO2 expression by human PBMCs. These data demonstrate for the first time that an anti-depressant alters expression of Ido1 and Ido2, identifying a possible new mechanism behind anti-depressant activity. Furthermore, we propose the assessment of PBMCs for anti-depressant responsiveness using IDO expression as a biomarker.
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Introduction
Currently, over 350 million people world-wide suffer from depression, with about 1 in 20 people reporting a depressive episode over the last year (Marcus et al., 2012) . Even worse, depression is predicted to become the leading cause of disease burden world-wide by the year 2030 (WHO, 2011) . The US population taking anti-depressants has doubled over the past 12 years further highlighting the extent of this problem (Kantor et al., 2015) . Considering the poor efficacy of anti-depressants for patients suffering from Major Depressive Disorders (MDD) (Anderson, 1998; Jakubovski et al., 2016; Kirsch and Sapirstein, 1998) , identifying additional targets for the creation of more-effective therapeutics is of utmost importance.
A subset of individuals with major depressive disorder present with evidence of an activated immune system (increased inflammatory biomarkers) and another subset have increased peripheral tryptophan metabolism to kynurenine (Kyn) (Murakami et al., 2016; Raison and Miller, 2011) . In patients with chronic elevation of inflammatory markers, anti-inflammatory drugs have potential anti-depressant efficacy (Raison, 2017) . Thus, patients with elevated Kyn production should benefit from therapeutics that http://dx.doi.org/10.1016/j.bbi.2017.02.010 0889-1591/Published by Elsevier Inc.
